HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Correspondence: View responses Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bateman, R. J. Articles by Holtzman, D. M. Search for Related Content PubMed Articles by Bateman, R. J. Articles by Holtzman, D. M.

Fluctuations of CSF amyloid-ß levels

Implications for a diagnostic and therapeutic biomarker

From the Departments of Neurology (R.J.B., G.W., J.C.M., D.M.H.), Pathology and Immunology (J.C.M.), and Molecular Biology & Pharmacology (D.M.H.), Alzheimer's Disease Research Center (R.J.B., J.C.M., D.M.H.), and Hope Center for Neurological Disorders (R.J.B., D.M.H.), Washington University School of Medicine, St. Louis, MO.

Address correspondence and reprint requests to Dr. Randall J. Bateman, Dept. of Neurology, Washington University School of Medicine, 660 S. Euclid, Box 8111, St. Louis, MO 63110; e-mail: batemanr{at}wustl.edu

Objective: To investigate the stability and time course of human CSF amyloid-ß (Aß) levels over hours.

Methods: Fifteen nondemented participants had CSF sampled hourly for up to 36 hours via indwelling lumbar catheter. CSF Aß_1-x, Aß_1-40, and Aß_1-42 were measured by ELISA in each hourly CSF sample.

Results: Significant variation in Aß levels of 1.5- to fourfold was detected over 36 hours of serially sampling in individual subjects. Aß₄₀, Aß₄₂, and Aß_1-X are highly correlated over time indicating that similar processes likely regulate the level of these species. On average, the fluctuations of Aß levels appear to be time of day or activity dependent.

Conclusion: Diagnostic and therapeutic trials that measure Aß should control for the time of CSF sampling to minimize variability.

Supported by grants from the US National Institutes of Health (NIH) grants K08 AG027091-01, Barnes Jewish Hospital Foundation Translational Research Grant, General Clinical Research Center (GCRC) MO1 RR00036, Alzheimer Disease Research Center (ADRC) P50 AG05681, P01 AG03991, and the Blanchette-Hooker Rockefeller Foundation.

Disclosure: The authors report no conflicts of interest.

Received August 24, 2006.

Accepted in final form November 6, 2006.

This article has been cited by other articles:

				N A Verwey, W M van der Flier, K Blennow, C Clark, S Sokolow, P P De Deyn, D Galasko, H Hampel, T Hartmann, E Kapaki, et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease Ann Clin Biochem, May 1, 2009; 46(3): 235 - 240. [Abstract] [Full Text] [PDF]

				M. A. Leissring The A{beta}Cs of A{beta}-cleaving Proteases J. Biol. Chem., October 31, 2008; 283(44): 29645 - 29649. [Abstract] [Full Text] [PDF]

				D. L. Brody, S. Magnoni, K. E. Schwetye, M. L. Spinner, T. J. Esparza, N. Stocchetti, G. J. Zipfel, and D. M. Holtzman Amyloid-{beta} Dynamics Correlate with Neurological Status in the Injured Human Brain Science, August 29, 2008; 321(5893): 1221 - 1224. [Abstract] [Full Text] [PDF]

				J. M. Ringman, S. G. Younkin, D. Pratico, W. Seltzer, G. M. Cole, D. H. Geschwind, Y. Rodriguez-Agudelo, B. Schaffer, J. Fein, S. Sokolow, et al. Biochemical markers in persons with preclinical familial Alzheimer disease Neurology, July 8, 2008; 71(2): 85 - 92. [Abstract] [Full Text] [PDF]

				J. R. Steinerman, M. Irizarry, N. Scarmeas, S. Raju, J. Brandt, M. Albert, D. Blacker, B. Hyman, and Y. Stern Distinct Pools of {beta}-Amyloid in Alzheimer Disease-Affected Brain: A Clinicopathologic Study Arch Neurol, July 1, 2008; 65(7): 906 - 912. [Abstract] [Full Text] [PDF]

				J. S. K. Kauwe, C. Cruchaga, K. Mayo, C. Fenoglio, S. Bertelsen, P. Nowotny, D. Galimberti, E. Scarpini, J. C. Morris, A. M. Fagan, et al. Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta deposition PNAS, June 10, 2008; 105(23): 8050 - 8054. [Abstract] [Full Text] [PDF]

				I. Klyubin, V. Betts, A. T. Welzel, K. Blennow, H. Zetterberg, A. Wallin, C. A. Lemere, W. K. Cullen, Y. Peng, T. Wisniewski, et al. Amyloid {beta} Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization J. Neurosci., April 16, 2008; 28(16): 4231 - 4237. [Abstract] [Full Text] [PDF]

				J. Shi and R. J. Bateman FLUCTUATIONS OF CSF AMYLOID-{beta} LEVELS: IMPLICATIONS FOR A DIAGNOSTIC AND THERAPEUTIC BIOMARKER Neurology, September 4, 2007; 69(10): 1063 - 1065. [Full Text] [PDF]

Correspondence: